Acute lymphoblastic leukaemia maintenance therapy dataset
Description
This anonymised dataset collection refers to patients with acute lymphoblastic leukaemia (ALL) treated at a single institution (Tata Medical Center, Kolkata, India) during the maintenance treatment phase (MT), as part of the Indian Collaborative Childhood Leukaemia (ICiCLe-ALL-14) treatment protocol (1). The MT phase spans 96 weeks, split into eight 12-week cycles Each patient dataset contains longitudinal records of blood counts (absolute neutrophil counts [ANC] and platelet counts [PLT]) and the accompanying drug doses of 6-mercaptopurine (6MP) and oral methotrexate (MTX) prescribed at each dose advice visit (indicated by the date and MT cycle) through the 96 weeks of MT. 6MP and MTX doses are recorded both as absolute doses (milligrams per week) and as dose intensities (DI, percentage proportion of protocol-recommended doses) of 6MP (6MP_DI) and MTX (MTX_DI). The companion dataset ‘cohort demographics’ provides relevant patient- (age at ALL diagnosis, sex) and disease-related information (ALL immune lineage [B or T-lineage] and highest white blood cell [WBC] count at presentation) This dataset allows analysis of dose titration practice in individual patients and in patient cohorts (2)(3). Dataset interpretation: For patient UPN_1, row 1 is interpreted as follows: The patient visited the hospital on 08/05/2014 (dd/mm/yyyy) during MT Cycle 1 and had a blood count test. Results showed ANC and PLT counts of 1.148 x10^9/L and 186× 10^9/L, respectively. Based on these values, the physician prescribed 323 mg/week of 6MP, which corresponds to 99% 6MP dose intensity (6MP_DI) and 15.5 mg/week of MTX, which corresponds to 100% MTX dose intensity. For dose intensity calculations, prescribed doses are reported as a proportion of protocol-recommended doses of 6MP (420 mg/sqm/week) and MTX (20 mg/sqm/week) (1). BSA or body surface area (recorded in square metres, sqm) information is used for calculation of protocol-recommended doses. References: 1. Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R, Arora B, Narula G, Sinha S, Roy P, Gogoi MP. Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials. 2022;23:102. 2. Mungle T, Mahadevan A, Krishnan S. allMT: Acute Lymphoblastic Leukemia Maintenance Therapy Analysis. The Comprehensive R Archive Network 2023. https://CRAN.R-project.org/package=allMT. 3. Mahadevan A, Mungle T, Krishnan S. VIATAMIN: VIsualisation & Analysis Tool in ALL MaINtenance. ShinyApps 2023. https://ananyam.shinyapps.io/VIATAMIN/.
Files
Steps to reproduce
At Tata Medical Center Kolkata, India, patient-held MT data sheets, MT e-clinic logbook and electronic medical records entries containing blood counts, doses of 6MP and MTX, and patient demographics were digitized to create the dataset.